Glioblastoma is characterized by widespread genetic and transcriptional heterogeneity, yet little is known about the role of the epigenome in glioblastoma disease progression. Here, we present genome-scale maps of DNA methylation in matched primary and recurring glioblastoma tumors, using data from a highly annotated clinical cohort that was selected through a national patient registry. We demonstrate the feasibility of DNA methylation mapping in a large set of routinely collected FFPE samples, and we validate bisulfite sequencing as a multipurpose assay that allowed us to infer a range of different genetic, epigenetic, and transcriptional characteristics of the profiled tumor samples. On the basis of these data, we identified subtle differences between primary and recurring tumors, links between DNA methylation and the tumor microenvironment, and an association of epigenetic tumor heterogeneity with patient survival. In summary, this study establishes an open resource for dissecting DNA methylation heterogeneity in a genetically diverse and heterogeneous cancer, and it demonstrates the feasibility of integrating epigenomics, radiology, and digital pathology for a national cohort, thereby leveraging existing samples and data collected as part of routine clinical practice.
G
lioblastoma is a brain cancer with devastating prognosis. Even under the best available care, median survival is little more than 1 year, and very few patients live for more than 3 years 1, 2 . Despite intense efforts, there has not been much therapeutic progress over the last decade, and a series of phase 3 clinical trials with targeted agents have failed to improve overall survival (OS) [3] [4] [5] . Glioblastoma shows extensive temporal and spatial heterogeneity, which appears to contribute to therapeutic resistance and inevitable relapse. Prior research on tumor heterogeneity in glioblastoma has focused mainly on its genomic and transcriptomic dimensions [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The role of the epigenome in glioblastoma disease progression is much less understood, although recent studies using DNA methylation microarrays have identified characteristic differences in the DNA methylation profiles between subgroups of patients with glioblastoma [16] [17] [18] [19] .
Research in other cancers has demonstrated the power of DNA methylation sequencing for analyzing epigenetic heterogeneity.
For example, DNA methylation heterogeneity has been linked to clonal progression in prostate cancer 20 , low-grade glioma 21 , esophageal squamous cell carcinoma 22 , and hepatocellular carcinoma 23 . Moreover, new measures of DNA methylation heterogeneity, such as epiallele burden, proportion of discordantly methylated reads (PDR), and DNA methylation inferred regulatory activity (MIRA), have been linked to clinical variables in acute myeloid leukemia 24 , chronic lymphocytic leukemia 25 , and Ewing sarcoma 26 .
To investigate the contribution of epigenetics to temporal and spatial heterogeneity in glioblastoma, we established genome-scale maps of DNA methylation for a glioblastoma progression cohort of patients with no mutation in the isocitrate dehydrogenase gene (IDHwildtype; primary glioblastoma) and with matched samples available from primary and recurring tumors (2-4 successive tumor resections per patient). This cohort was selected through the population-based Austrian Brain Tumor Registry 27 and reflects routine clinical practice for glioblastoma at eight contributing medical centers across Austria.
A full list of affiliations appears at the end of the paper. Table 2 ). The median number of unique CpGs for FFPE samples (1, 839, 096) was lower than for fresh-frozen samples (3, 846, 772 ) but higher than for an ethanol-based fixation method 33 (1, 005, 828) tested by one of the centers that contributed tumor samples ( Supplementary Fig. 1c and Supplementary Table 2 ). Bisulfite conversion rates, which assess the selective chemical conversion of unmethylated cytosines, were indicative of high-quality data: ~99% of genomic cytosines outside of CpGs were read as thymines, the mean underconversion rate on unmethylated spike-in controls was ~1%, and the mean overconversion rate on methylated spike-in controls was ~2% ( Supplementary  Fig. 1d and Supplementary Table 2 ).
500,000 unique CpGs (Supplementary
The DNA methylation profiles showed the typical distribution of DNA methylation across promoters, enhancers, and genome-wide tiling regions ( Supplementary Fig. 1e ), with a tendency toward lower DNA methylation levels in lower-quality samples ( Supplementary  Fig. 1f ). To check for batch effects in the DNA methylation data 34 , we applied multidimensional scaling to the entire dataset and found the expected clustering of the samples by material type (FFPE versus fresh-frozen) and disease diagnosis, whereas none of the investigated sources of batch effects (center, date, etc.) had a readily discernable effect on our dataset ( Supplementary Fig. 1g ).
Comparing locus-specific DNA methylation between matched primary and recurring tumors ( Supplementary Fig. 1h ), we observed high correlations across the genome (r > 0.94 for 5-kb tiling regions). Accordingly, zooming into selected genomic loci revealed interpatient heterogeneity but no major differences between primary and recurring tumors ( Fig. 1c and Supplementary Fig. 2a,b) .
We specifically investigated the promoter of the MGMT gene (Fig. 1c) , whose DNA methylation status correlates with sensitivity to alkylating chemotherapy 35 . The MGMT promoter was unmethylated in the majority of samples based on our RRBS data ( Supplementary Fig. 2c ), with the caveat that a robust and accurate assessment of DNA methylation at the MGMT promoter is technically challenging [35] [36] [37] . Patients with a methylated MGMT promoter in their recurring tumors showed significantly better progression-free survival (PFS) and OS than patients with an unmethylated MGMT promoter (Supplementary Fig. 2d and Supplementary Table 3) , and a similar association of MGMT promoter methylation with OS was observed for the primary tumors when combining the progression and validation cohort ( Supplementary Fig. 2d ).
To provide further context for our IDH-wildtype primary glioblastoma cohort, we performed RRBS on primary and recurring tumors of 14 patients from the same population who were diagnosed with oligodendroglioma, astrocytoma, or secondary glioblastoma and harbored a mutated IDH gene. The DNA methylation profiles of these tumors showed G-CIMP characteristics as expected based on previous research 38 ( Fig. 1d) , thus providing additional validation for our genome-scale DNA methylation sequencing of FFPE material.
We also evaluated bioinformatic inference as a way of obtaining copy number aberration (CNA) profiles directly from RRBS data. We indeed detected various CNAs previously described in glioblastoma ( Supplementary Fig. 3a ). Of particular interest, chromosome 10q deletions in recurring tumors (which affect MGMT and correlate with increased sensitivity to alkylating chemotherapy 39 ) were associated with longer survival (Supplementary Fig. 3b ). On the basis of the inferred CNA data, we also verified that none of our primary glioblastoma samples harbored the 1p19q codeletion, thereby excluding the presence of any misclassified cases of anaplastic oligodendroglioma ( Supplementary Fig. 3c ). Finally, we validated the accuracy of our RRBS-based CNA analysis in 43 glioblastoma samples, for which we generated low-coverage whole-genome sequencing data, and we observed high concordance between both methods ( Supplementary Fig. 4a,b) .
DNA methylation profiling was performed on archival formalinfixed paraffin-embedded (FFPE) samples using reduced representation bisulfite sequencing (RRBS) [28] [29] [30] . Compared to Infinium microarrays, our optimized RRBS protocol yields higher genomic coverage 31 and works well on degraded DNA from FFPE samples of variable quality 32 . Moreover, it provides single-CpG and single-allele resolution: in RRBS, each sequencing read captures the DNA methylation status of individual CpGs in one single allele from one single cell, which enables high-resolution analysis of epigenetic tumor heterogeneity [24] [25] [26] . Our full dataset comprises 499 RRBS-based DNA methylation profiles, of which 426 were derived from FFPE samples. These data not only provide a map of epigenetic heterogeneity in glioblastoma, but also allowed us to infer transcriptional subtypes, copy number aberration, O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation, and glioma CpG island methylator phenotype (G-CIMP). Our study thus validates the feasibility and relevance of DNA methylation sequencing in large cohorts of routinely collected clinical FFPE tumor samples.
To put the DNA methylation data into a broader disease context, we obtained comprehensive patient and tumor data that allowed us to identify DNA methylation patterns predictive of immune cell infiltration and tumor microenvironment, progression-linked loss of DNA methylation at the promoters of genes encoding components of the Wnt signaling pathway, and stronger survival associations for recurring tumors than for primary tumors.
In summary, our study provides a detailed picture of temporal and spatial heterogeneity in glioblastoma, a widely usable resource of DNA methylation profiles and associated annotation data, proofof-concept for DNA methylation sequencing in large FFPE sample sets collected as part of routine diagnostics, and an integrative analysis of DNA methylation with various types of clinical, histopathological, and radiological information.
Results
DNA methylation sequencing in a cohort of matched primary and recurring glioblastoma tumor samples. To investigate the DNA methylation dynamics associated with glioblastoma disease progression, we established a richly annotated dataset of patients with primary glioblastoma (IDH-wildtype status) who underwent surgery at least twice, with tumor samples routinely collected during the initial tumor resection and at least once upon recurrence (Fig. 1a) . In total, 112 such patients were selected through the population-based Austrian Brain Tumor Registry 27 (Fig. 1b and  Supplementary Table 1 ) and included in our progression cohort.
Because a second surgery at relapse is rarely performed in patients who are frail or have many comorbidities, the patients in the progression cohort were on average younger (median age at diagnosis, 58 years) and lived longer (median OS, 23.9 months) than the average registry patient (median age at diagnosis, 63 years; median OS, 8 months). To control for this selection bias, we included a validation cohort of 105 patients with primary glioblastoma (IDH-wildtype status) who underwent resective surgery only once. These patients (median age at diagnosis, 65 years; median OS, 8.8 months) were much more representative of the unselected Austrian patient population ( Supplementary Fig. 1a,b) .
For each of these tumor samples, we established genome-scale DNA methylation profiles using RRBS, and we collected detailed time-and sample-matched patient and tumor data, including magnetic resonance imaging (MRI), quantitative pathology capturing tumor morphology, proliferative activity, and microenvironment, and clinical variables, including patient survival. In the presented analyses, we systematically integrated these datasets using statistical methods and machine learning (Fig. 1a) . All data are publicly available through the supplementary website (see URLs).
RRBS profiling was successful for all tested samples, and 96% of the resulting DNA methylation profiles included more than Fig. 1 | DNA methylation landscape of glioblastoma disease progression. a, Integrative analysis of longitudinal DNA methylation data (RRBS) with matched MRI data (morphology, segmentation), clinical annotation data (treatment, progression, IDH mutation status), and histopathological data (segmentation, morphology, immunohistochemistry) using statistical methods and machine learning. TMZ, temozolomide; RTX, radiation therapy; PC, palliative care. b, Overview of the progression cohort, summarizing the disease courses of 112 patients with primary glioblastoma (IDH-wildtype) who underwent at least two tumor resections (ordered by time of first surgery). c, DNA methylation profiles for primary (t = 1) and recurring (t = 2) tumors at three glioblastoma-linked gene loci (SFRP2, PLXNB2, MGMT) in the progression (Prog.) and validation (Val.) cohorts. Gene annotations and epigenome segmentations for astrocytes were obtained from the WashU EpiGenome Browser (see URLs). d, DNA methylation levels at individual CpGs indicative of G-CIMP are shown for IDH-mutated reference samples (which are G-CIMP-positive) and for the primary glioblastoma (IDH-wildtype) samples from the study cohort (which are G-CIMP-negative). The DNA methylation fold change between IDH-mutated and IDH-wildtype samples is based on published data for G-CIMP marker CpGs 38 .
Prediction of transcriptional subtypes in glioblastoma on the basis of DNA methylation. Large-scale genome and transcriptome profiling efforts have defined three transcriptional subtypes of glioblastoma with distinct molecular and clinical characteristics: classical, mesenchymal, and proneural 16, 40 (a fourth 'neural' subtype has also been described but appears to be an artifact of contaminating nontumor tissue and has been disregarded in recent research 15, 41 ). Because transcriptome profiling is challenging to perform on routinely collected FFPE samples, we tested whether these transcriptional subtypes can be inferred from RRBS data-which would remove the dependence on high-quality RNA for transcriptional subtyping (Fig. 2a) .
Using machine learning (L2-regularized logistic regression) and training data from The Cancer Genome Atlas (see URLs), we validated RRBS-based prediction of transcriptional subtypes in 37 fresh-frozen glioblastoma samples, for which we generated matched RRBS and RNA sequencing (RNA-seq) data. Most samples were concordantly assigned by the DNA methylation-based and RNAbased classifiers ( Supplementary Fig. 5a,b) , and the receiver operating characteristic (ROC) area under curve (AUC) values exceeded 0.8 for all three transcriptional subtypes ( Supplementary Fig. 5c ). Among the (few) discordant cases, we observed reduced confidence in the RNA-based predictions, suggesting that the true accuracy of DNA methylation-based subtype classification may be roughly on par with RNA-based classification ( Supplementary Fig. 5d ).
By training and applying individual classifiers for RRBS-based subtype prediction, we obtained subtype prediction probabilities with high ROC AUC values (> 80%) for most tumor samples in our dataset ( Supplementary Fig. 6a ). According to these predictions, all three transcriptional subtypes were well-represented among the IDH-wildtype primary glioblastoma samples of the progression and validation cohort ( Fig. 2b and Supplementary Fig. 6b,c) . In contrast, the IDH-mutated oligodendroglioma/astrocytoma/glioblastoma tumor samples were almost invariably assigned to the proneural subtype ( Supplementary Fig. 6d ).
Although the subtype prediction probabilities primarily reflect the confidence with which a sample was assigned to each of the transcriptional subtypes, we used them also as an indicator of the relative contribution of each subtype to individual tumor samples, thus providing an initial assessment of intratumor heterogeneity. Most tumor samples showed signatures of more than one transcriptional subtype ( Fig. 2b and Supplementary Fig. 6b ), consistent with recent single-cell RNA-seq data that identified similar heterogeneity within individual samples 11 . Moreover, five out of six patients with multisector samples displayed at least two different predominant transcriptional subtypes ( Fig. 2c and Supplementary Fig. 6e-g ), and about half of the patients changed their predominant transcriptional subtype between the primary and recurring tumor (Fig. 2d) .
Predicted transcriptional subtypes in the recurring tumor (but not in the primary tumor) were associated with patient survival (Fig. 2e and Supplementary Fig. 6h )-the mesenchymal subtype being associated with the worst prognosis and the classical subtype with the best prognosis. Moreover, patients whose tumors switched to the mesenchymal subtype had particularly poor PFS and OS (Fig. 2e) .
To investigate epigenetic differences between transcriptional subtypes, we compared the DNA methylation profiles between tumors that were confidently assigned to one specific subtype (Fig. 2f) . Through genomic region enrichment analysis for the differentially methylated CpGs using locus overlap analysis (LOLA) 42 , we identified a strong enrichment of binding sites for the chromatin proteins EZH2, KDM4A, RBBP5, and SUZ12 among regions hypomethylated in the mesenchymal subtype (Fig. 2g) .
We also calculated MIRA scores 26 for each tumor (Fig. 2h) . MIRA scores measure the local depletion of DNA methylation across all binding sites of a specific chromatin protein, and high MIRA scores indicate a strong dip in DNA methylation levels, indicative of high regulatory activity of the chromatin protein. We observed significantly increased MIRA scores for CTCF, EZH2, and KDM4A in the mesenchymal subtype, whereas MIRA scores for key regulators of pluripotency (POU5F1 (OCT4), NANOG, SOX2) were decreased (Fig. 2i, Supplementary Fig. 7a ,b, and Supplementary Table 4) .
To investigate the role of EZH2 in more detail, we measured the fraction of EZH2-positive cells in the tumors by immunohistochemistry but did not observe an association with MIRA scores for EZH2 ( Supplementary Fig. 7c ) nor with transcriptional subtypes (Supplementary Fig. 7d ). These results indicate that the increased regulatory activity of EZH2 in the mesenchymal subtype (predicted by DNA methylation depletion at EZH2-binding sites) is not the result of an increased fraction of EZH2-expressing cells but may rather reflect cell-intrinsic epigenome regulation.
Finally, to connect the differences observed between transcriptional subtypes to the wider landscape of epigenome regulation, we obtained cell type-specific enhancer annotations from the Table 3 . P values were calculated using a two-sided log-rank test. f, Heatmap displaying the DNA methylation levels of the most differential CpGs between the three transcriptional subtypes, excluding CpGs with more than 100 missing values. Only tumor samples that were classified with high class probabilities (> 0.8) for their dominant subtype were included in this analysis. Cla, classical; Mes, mesenchymal; Pro, proneural. g, LOLA region set enrichment analysis for differentially methylated CpGs between transcriptional subtypes (binned into 1-kb tiling regions). Region sets from astrocytes or embryonic stem cells with adjusted P < 0.001 are shown. P values were calculated using a two-sided Fisher's exact test. Adjustment for multiple testing was performed using the Benjamini-Yekutieli method. h, Schematic depicting the calculation of MIRA scores. High MIRA scores reflect local demethylation at the binding sites of a specific transcription factor across the genome, which indicates high regulatory activity of that factor. i, DNA methylation profiles (top) and corresponding MIRA scores (bottom) for three sets of transcription factor binding sites that were hypomethylated in the mesenchymal subtype (CTCF, EZH2, KDM4A) and for the binding sites of three key regulators of pluripotency (POU5F1 (OCT4), NANOG, SOX2). The number of tumor samples (n) in each group is provided in Supplementary Table 4 . P values were calculated using a two-sided Wilcoxon rank-sum test. In box-and-whisker plots, the upper and lower hinges represent the 75th and 25th percentiles, respectively. The center line represents the median. The whiskers extend to the largest and smallest values within 1.5 times the interquartile range. EZH2  SUZ12  RBBP5  PHF8  CTBP2  POLR2A  CHD1  TAF1  HDAC2  TBP  CTCF  RAD21  SIN3A  EGR1  SAP30  ZNF143  BACH1  POL2  TAF7  MAX  NRF1  YY1  USF1  GABP  TCF12  SP1  POL24H8  CHD2  USF2  SIN3AK20  GTF2F1  MXI1  CMYC  SP4  TEAD4 Months Months P = 0.0024 P P = 0.33 P P = 0.011 P P = 0.018 P P (Cla, Mes) = 0.0000000382 P P (Cla, Mes) = 0.00000488 P P (Cla, Mes) = 0.000184 P P P (Cl M ) 000000000884 (Cla, Mes) = 0.00000000884 P P P P (Cla Mes) 0 00000113 (Cla, Mes) = 0.00000113 P P P (Cla, Pro) = 0.24 P P (Cla, Pro) = 0.42 P P (Cla, Pro) = 0.84 P P (Cla, Pro) = 0.13 P P P (Cla, Pro) = 0.75 P P P (Mes, Pro) = 0.025 P P (Mes, Pro) = 0.0083 P P (Mes, Pro) = 0. Roadmap Epigenomics Project 43 , including data for embryonic stem cells (as an undifferentiated cell state) and astrocytes (used as reference because of the presumed similarity between astrocytes and the cell-of-origin from which glioblastoma develops). After applying MIRA analysis to these two sets of enhancer regions, we indeed observed characteristic, subtype-specific patterns of regulatory activity ( Supplementary Fig. 7e,f) .
Linking DNA methylation differences to changes in the tumor microenvironment. To test whether the RRBS profiles capture relevant aspects of the tumor microenvironment, we analyzed them together with matched histopathology and MRI data ( Fig. 3 and Supplementary Figs. 8a-f and 9a-g ). Specifically, the tumor microenvironment was assessed by immunohistochemistry for markers of immune cell types (CD3, T cells; CD8, cytotoxic T cells; CD68, macrophages), subpopulations (CD163, infiltrating macrophages; FOXP3, anti-inflammatory T cells; CD45ro, memory T cells), and functional characteristics (CD80, costimulatory signal to T cell activation; Ki-67 (MIB-1), cellular proliferation status).
We observed significant differences in the immune cell infiltration between the three transcriptional subtypes (Fig. 3a,b and Supplementary Fig. 8a ). The highest number of immune cells was found in tumors of the mesenchymal subtype (in concordance with previous work 44 ). This subtype also showed lower cell density and large necrotic areas in histopathology (Supplementary Fig. 8b-d) , as well as a tendency toward increased tumor size, fewer vital tumor areas, and increased edema in the MRI data ( Supplementary  Fig. 9a-c) .
As revealed by combining data across subtypes, high levels of CD68-positive cells (macrophages of all types) were associated with poor prognosis in recurring tumors, and high levels of CD163-positive cells (tumor-infiltrating macrophages) were associated with poor prognosis in both primary and recurring tumors specifically in the progression cohort ( Fig. 3c and Supplementary Fig. 8f ). Our results thus confirm the described prognostic value of CD68 and CD163 stainings 45, 46 .
Comparing matched primary and recurring tumors, we observed significantly higher immune cell infiltration upon recurrence (Fig. 3d,e) ; lower cell density and fewer necrotic areas in histopathology ( Supplementary Fig. 8b ,c,e); and decreased necrotic volume, decreased contrast-enhancing (active) tumor mass, increased edema, and stable tumor size in MRI ( Supplementary  Fig. 9a ,b,d). On average, patients with less necrotic or contrastenhancing (active) tumor mass upon recurrence had longer PFS ( Supplementary Fig. 9e ).
When we stratified patients according to prognostically relevant progression types (classic T1, cT1 relapse/flare-up, and T2 diffuse) 47 on the basis of MRI ( Supplementary Fig. 9f ,g), we found that primary and recurring tumors from patients displaying the cT1 relapse/flare-up subtype had lower infiltration of proinflammatory immune cell types (CD3, CD8, CD68) and a lower fraction of MIB-1-positive, proliferating cells (Fig. 3f) .
Using machine learning, we were able to predict various patient and tumor properties from the RRBS profiles ( Fig. 3g and Supplementary Fig. 10 ). For example, DNA methylation distinguished well between samples with a high versus low percentage of necrosis in histopathology (progression cohort ROC AUC, 0.87; validation cohort ROC AUC, 0.95). The same was true for high versus low levels of specific immune cell infiltrates, including CD163-positive cells (progression cohort, 0.87; validation cohort, 0.84), CD68-positive cells (progression cohort, 0.79, validation cohort, 0.75), CD45ro-positive cells (progression cohort, 0.94), CD3-positive cells (progression cohort, 0.91), and CD8-positive cells (progression cohort, 0.83). These results suggest that DNA methylation data can be used to infer immune cell infiltration in a similar way to that shown for RNA-expression profiles 15, 48 , with the advantage of full compatibility with routinely collected FFPE material.
Linking DNA methylation differences to tumor cell-intrinsic properties. Histopathological analysis assesses not only the tumor microenvironment but also tumor cell-intrinsic properties, such as cell proliferation and subcellular morphology, which constitute an additional layer of information that we integrated with the DNA methylation data.
In our dataset, the percentage of proliferating cells (based on immunohistochemistry for MIB-1) was significantly lower in tumors of the mesenchymal subtype ( Fig. 4a ) but showed no consistent changes between primary and recurring tumors ( Supplementary  Fig. 11a ). Nevertheless, high proliferation in the recurring tumors (but not in the primary tumors) was associated with longer PFS ( Fig. 4b and Supplementary Fig. 11b ). This perhaps counterintuitive observation may be explained by the fact that early relapses tend to occur while the patient receives chemotherapy (which impedes cell proliferation); moreover, high proliferation may render tumors more sensitive to cytostatic chemotherapy.
DNA methylation patterns discriminated with high accuracy between tumors characterized by high versus low proliferation rates (progression cohort ROC AUC, 0.91; validation cohort ROC AUC, 0.84) ( Fig. 4c and Supplementary Fig. 11c ). This was not because of differences in mean DNA methylation levels indicative of global hypomethylation or hypermethylation (Fig. 4d ,e and Supplementary  Fig. 11d ). Rather, highly proliferating tumors showed intermediate DNA methylation levels at discriminatory regions, whereas tumors with low proliferation rates showed more extreme DNA methylation patterns ( Fig. 4e and Supplementary Fig. 11e ).
Glioblastoma is a histologically polymorphic cancer, a property that we quantified by determining nuclear eccentricity (a measure of elongated shape) and the variability of this measure. Neither Table 3 . P values were calculated using a two-sided log-rank test. In c and g, shaded regions denote 95% confidence intervals. d, Level of tumor-infiltrating immune cells in samples originating from the first (1, primary tumor), second (2, recurring tumor), or third (3, where available) surgery of the patients in the progression cohort, and for the first (and only) surgery in the validation cohort. P values were calculated using a two-sided Wilcoxon rank-sum test. e, Illustrative immunohistochemical stainings for three marker proteins (CD68, CD8, CD163) in three individual patients with changing levels of tumor-infiltrating immune cells between primary and recurring tumors. f, Levels of tumor-infiltrating immune (CD3, CD8, CD68) cells and proliferating (MIB-1-positive) cells compared between patients that were assigned to different progression types on the basis of MRI: classic T1 (claT1), cT1 relapse/flare-up (cT1), and T2 diffuse (T2). P values were calculated using a two-sided Wilcoxon rank-sum test. g, ROC curves for DNA methylation based prediction of immune cell infiltration levels. n denotes the number of tumor samples in each group. The number of tumor samples (n) for the association tests (a,d,f) is provided in Supplementary Table 4 . 
P (cla,cT1) = 0.125 P P (cla,T2 ) = 0.0105 P P (cT1,T2 ) = 0.0167 P CD3 + cell fraction high vs. low value was significantly different between primary and recurring tumors ( Supplementary Fig. 11f ). However, tumors that shifted to a sarcoma-like phenotype (e.g., secondary gliosarcoma) 49 upon recurrence showed an increase in nuclear eccentricity and a decrease in its variability (Fig. 4f-g ), accompanied by an increase in CD8 immune cell infiltration, cell proliferation (MIB-1-positive cells), and relative tumor mass in the recurring tumor (Fig. 4h) .
DNA methylation patterns predicted nuclear eccentricity (ROC AUC, 0.8) and its variability (0.81) in the progression cohort (Fig. 4i) but not in the validation cohort (where ROC AUC values were below 0.7 for both measures), which might be due to decreased variability of these features in the validation cohort ( Supplementary  Fig. 11f ). Patients with shape-shifting tumors (i.e., classic to sarcoma-like) displayed significantly shorter PFS and a trend toward reduced OS (Fig. 4j) .
DNA methylation heterogeneity and temporal dynamics between primary and recurring tumors. Each RRBS read captures the DNA methylation pattern of an individual cell, allowing us to investigate intratumor heterogeneity without the need for single-cell sequencing. We used two complementary approaches to investigate epigenetic heterogeneity at gene promoters (Fig. 5a ). First, erosion of DNA methylation patterns was measured using the proportion of discordant reads (PDR) 25 . This score is high for regions with many reads that contain both methylated and unmethylated CpGs. Second, subclonal heterogeneity was measured by epiallele entropy (EPY) 50 . This score is high for regions with many different allelic DNA methylation patterns.
In the progression cohort, both approaches identified substantial intratumor heterogeneity and patient-to-patient variability but no clear trend toward higher or lower heterogeneity in primary or recurring tumors ( Fig. 5b and Supplementary Fig. 12a ). In the validation cohort (which comprises older patients with shorter survival), both heterogeneity measures had significantly lower values than in the progression cohort (Fig. 5b) .
To investigate the epiallele composition from which the PDR and EPY scores are calculated (i.e., the distribution of observed DNA methylation patterns at four subsequent CpGs covered by the same RRBS read), we focused on the samples with the highest (green) and lowest (orange) mean PDR or EPY scores (Fig. 5b) . As expected for gene promoters, the most frequently observed epiallele was consistently that of an unmethylated read (DNA methylation pattern: 0000). In contrast, there was large sample-to-sample variation in the ratio of epialleles that were fully methylated (1111) or heterogeneously methylated (for example, 1001 or 0111) (Fig. 5c , bottom panel). Samples with high mean PDR and/or EPY scores generally showed greater diversity in their epiallele composition than those with low heterogeneity scores (Fig. 5c, upper panel) .
Heterogeneity scores (PDR and EPY) were weakly correlated with tumor size as measured by MRI ( Supplementary Fig. 12b ), and we observed a significant positive association between increased DNA methylation erosion (mean PDR) and PFS specifically in the primary tumors of the progression cohort (Fig. 5d) . In contrast, no such association was found for EPY nor in the validation cohort ( Fig. 5d and Supplementary Fig. 12c ).
We next investigated temporal heterogeneity by analyzing promoter-associated changes in DNA methylation between primary and recurring tumors of the same patient. A larger number of DNA methylation differences was observed in patients with a shorter time between first and second surgery (Fig. 5e) , suggesting that aggressive tumors may be characterized by high epigenetic plasticity.
The number of genomic regions that displayed changes in their epiallele composition (so-called eloci 50 , illustrated in Fig. 5a ) varied considerably between patients ( Supplementary Fig. 12d) ; however, these patient-to-patient differences were not associated with clinical outcome (Supplementary Fig. 12e ) nor with the time span between first and second surgery ( Supplementary Fig. 12f ). The regions identified as eloci also did not show any evidence of selection based on their position relative to the nearest gene ( Supplementary Fig.  12g ). However, we did observe an enrichment of EZH2-binding sites among these regions ( Supplementary Fig. 12h ), providing further support for connections between EZH2 and epigenome deregulation in glioblastoma.
In search for regulatory mechanisms that may be involved in glioblastoma disease progression, we focused on the small number of promoters with a strong progression-associated change in DNA methylation across multiple patients (Fig. 6a) . Most of these promoters showed consistent trends toward either gain or loss of DNA methylation upon recurrence (Fig. 6b) . When we classified the individual patients into those that followed the cohort-level trend in differential DNA methylation (trend patients) and those that did not (antitrend patients) (Fig. 6b, c) , the trend patients showed worse prognosis (Fig. 6d) , suggesting that some of the observed differences may indeed contribute to aggressive recurrent tumors.
Biological pathway analysis identified an enrichment of annotations referring to neural development and apoptosis signaling among genes whose promoters gained DNA methylation during disease progression; in contrast, genes whose promoters lost DNA methylation were enriched in the Wnt signaling pathway and T cell activation (Fig. 6e) . Corroborating this observation, when we classified patients according to whether they gained or lost DNA methylation across the promoters of Wnt signaling genes, we observed a significant association between loss of DNA methylation and reduced survival (Fig. 6f) .
Finally, to test the global association between DNA methylation and survival of patients with glioblastoma, we trained and evaluated In box-and-whisker plots in a, f, and h, the upper and lower hinges represent the 75th and 25th percentiles, respectively. The center line represents the median. The whiskers extend to the largest and smallest values within 1.5 times the interquartile range. P values were calculated using a two-sided Wilcoxon rank-sum test. b, Kaplan-Meier plots showing PFS and OS stratified by the fraction of proliferating (MIB-1-positive) cells. P values were calculated using a two-sided log-rank test. In b, c, i, and j, shaded regions denote 95% confidence intervals. c, ROC curves for DNA methylation-based prediction of the fraction of proliferating (MIB-1-positive) cells. n denotes the number of tumor samples in each group. d, Clustered heatmap for the column-scaled DNA methylation levels of the most predictive genomic regions (5-kb tiling regions) from the classifier predicting the fraction of proliferating (MIB-1-positive) cells. e, Histogram showing the distribution of DNA methylation levels across the most predictive genomic regions from the classifier predicting the fraction of proliferating (MIB-positive) cells. f, Average nuclear eccentricity (AVG) and its coefficient of variation (COV) for tumors that shift to a sarcoma-like phenotype during disease progression and those that retain a stable histological phenotype. g, Illustrative H&E stains of matched primary and recurring tumors from one patient that shifted to a sarcoma-like phenotype. h, Comparison of additional tumor properties (as indicated by the y axis labels) between tumors that shifted to a sarcoma-like phenotype during disease progression and those that retained a stable histological phenotype. i, ROC curves for DNA methylation-based prediction of average nuclear eccentricity and its coefficient of variation. n denotes the number of tumor samples in each group. j, Kaplan-Meier plots showing PFS and OS stratified by whether or not tumors shifted to a sarcoma-like phenotype. P values were calculated using a two-sided log-rank test. The number of tumor samples (n) for the association tests (a,f,h) is provided in Supplementary Table 4 . The number of patients (n) in the Kaplan-Meier analysis (b,j) is provided in Supplementary Table 3 . Regions that undergo extensive changes in their epiallele composition (i.e., in the distribution of subclonal DNA methylation patterns) are referred to as eloci 50 (Locus 2 and 3, bottom row). b, Sample-wise PDR and EPY scores averaged across promoter regions for first (t = 1, primary tumor) and second (t = 2, recurring tumor) surgery of the progression cohort and first (and only) surgery of the validation cohort. The samples with the 20% highest and lowest scores are shown in green and orange, respectively. P values were calculated using a two-sided Wilcoxon rank-sum test. n denotes the number of tumor samples. In box-and-whisker plots, the upper and lower hinges represent the 75th and 25th percentiles, respectively. The center line represents the median. The whiskers extend to the largest and smallest values within 1.5 times the interquartile range. c, Relative epiallele frequencies across promoter regions for all samples highlighted in green and/or orange in b. Samples are ordered by epiallele diversity, and samples with high epiallele diversity (left) tend to show high PDR and/or EPY (green dots). For clearer visualization, the '0000' majority epiallele with a frequency of ~70-90% is not displayed. 0, unmethylated; 1, methylated. d, Kaplan-Meier plots showing PFS and OS stratified by PDR and EPY values, respectively. The number of patients (n) is provided in Supplementary Table 3 . P values were calculated using a two-sided log-rank test. In d and e, shaded regions denote 95% confidence intervals. e, Scatterplot depicting the (negative) association of the number of differentially methylated promoters between primary and recurring tumor samples (normalized to the number of assessed promoters) and the time between first and second surgery. DPM, differentially methylated promoters per million assessed promoters. r, Pearson correlation coefficient. P was calculated with a one-sided Pearson's test. n denotes the number of tumor samples. Promoters that were differentially methylated in at least five patients are highlighted. n denotes the number of data points (samples × promoters). b, Bar plots (top) depicting the number of patients that show significant gain or loss of DNA methylation at the differentially methylated promoters highlighted in a (color-coded in turquoise and red); dot and line plots (bottom) showing the change in DNA methylation associated with disease progression (percentage points, pp) for patients following (red) or not following (blue) the cohort trend. Trend lines were calculated using the loess() function in R. c, Histogram showing the number of 'trend' and 'antitrend' patients based on the Manhattan distance between the maximal trend at differentially methylated promoters (DNA methylation values of 0% or 100%, respectively) and the observed difference in DNA methylation for each patient. d, Kaplan-Meier plots showing PFS and OS for trend and antitrend patients stratified as in c. P values were calculated using a two-sided log-rank test. In d, f, and g, shaded regions denote 95% confidence intervals. e, Gene set enrichment analysis of those genes in b that recurrently gain (top) or lose (bottom) promoter DNA methylation during disease progression. n denotes the number of genes. f, Kaplan-Meier plots showing PFS and OS stratified by progression-linked changes in DNA methylation at the promoters of Wnt signaling genes (top and bottom 30% of patients included). P values were calculated using a two-sided log-rank test. g, ROC curve and clustered heatmap for DNA methylation-based prediction of OS, comparing patients with survival above the median in the progression cohort ('long') to patients with survival below the median in the validation cohort ('short'). n denotes the number of tumor samples in each group. h, LOLA region set enrichment analysis for the top-2,000 tiling regions (5 kb) most predictive of OS. Region sets from astrocytes, brain tissue, or embryonic stem cells with an adjusted P < 0.001 are shown. P values were calculated using a two-sided Fisher's exact test. Adjustment for multiple testing was performed using the Benjamini-Yekutieli method. The number of patients (n) in the Kaplan-Meier analysis (d,f) is provided in Supplementary Table 3 .
a machine-learning classifier that distinguishes between the patient group with the shortest survival (patients from the validation cohort whose survival was below the cohort median) and the patient group with the longest survival (patients from the progression cohort whose survival was above the cohort median). Crossvalidation confirmed the predictive power of DNA methylation (ROC AUC, 0.91) (Fig. 6g) , and the predictive regions were enriched for poised enhancers and genomic regions that are polycomb-repressed in brain tissue or inactive (quiescent, heterochromatin) in astrocytes and embryonic stem cells (Fig. 6h) .
Discussion
Longitudinal analysis of matched tumor samples has great potential for charting cancer progression and therapy resistance, yet such cohorts are rare and difficult to obtain 51 . By leveraging a national patient registry and routinely collected FFPE tumor blocks, we established a progression cohort comprising 112 primary glioblastoma patients that had undergone at least two tumor resections. To account for bias toward younger and healthier patients in the progression cohort, we also assembled a validation cohort (n = 105) that is broadly representative of primary glioblastoma patients in the Austrian population. We established genome-scale DNA methylation maps for all tumors and collected matched clinical, histopathological, and MRI data, thereby enabling a comprehensive analysis of glioblastoma disease progression and epigenetic tumor heterogeneity.
From a technical perspective, our study was facilitated by an optimized RRBS protocol that provided single-CpG and singleallele DNA methylation data for a median of ~2 million and up to ~4 million unique CpGs based on small quantities of FFPE material. The RRBS data allowed us to infer a broad range of tumor properties, including known biomarkers such as G-CIMP status, MGMT promoter methylation, and chromosome 1p19q codeletion. We also established the utility of RRBS data for predicting glioblastoma transcriptional subtypes 16, 40 , thus extending this candidate biomarker to routinely collected FFPE samples (which are challenging to profile using RNA-seq). Finally, the single-allele resolution of RRBS provided initial insights into epigenetic tumor heterogeneity in glioblastoma, and it distinguishes our approach from recent studies that used the Infinium microarray platform for diagnostic classification of brain tumors 17, 52 . Connecting the DNA methylation data to a detailed histopathological characterization of the tumors, we found DNA methylation to be predictive of immune cell infiltration, the extent of necrosis, and the shape of tumor cell nuclei. Moreover, DNA methylation depletion at regulatory elements identified footprints of increased EZH2-binding activity in glioblastoma tumors of the mesenchymal subtype, which were characterized by the worst survival. We also observed associations between immune cell infiltration and MRIbased subtypes of glioblastoma disease progression, and we identified DNA methylation patterns that predicted the percentage of proliferating cells inside a tumor, which was positively associated with PFS.
Between primary and recurring tumors, patient-specific differences in the DNA methylation profiles were largely retained, but we found several recurrent progression-associated changes. For example, we observed characteristic demethylation of the promoters of Wnt signaling genes in a subset of patients, which was associated with worse prognosis. Aberrant activation of the Wnt signaling pathway is seen in various cancers including glioblastoma, in which it has been linked to stemness, invasiveness, angiogenesis, and therapeutic resistance 53 . DNA methylation erosion (measured by the PDR score) and subclonal heterogeneity (EPY score) were variable across patients but similar between primary and recurring tumors-providing evidence against not only a therapy-induced increase in epigenetic heterogeneity, but also a decrease in epigenetic heterogeneity due to strong selective sweeps driven by therapy-resistant subclones. Nevertheless, we found an association between high levels of DNA methylation erosion in the primary tumors and longer PFS, suggesting that epigenetic heterogeneity may not always be a driver of progression (as it seems to be the case in leukemia 24, 25 ) but may under certain circumstances become a liability for a fast-growing solid tumor such as glioblastoma.
We observed characteristic similarities and differences between the progression cohort with its bias toward younger and healthier patients and the population-representative validation cohort. Although the frequency and heterogeneity of transcriptional subtypes were similar in both cohorts, the measures of epigenetic heterogeneity were significantly lower in the validation cohort. Finally, DNA methylation patterns accurately distinguished between patients with the longest and the shortest survival in the two cohorts.
In summary, our study establishes a rich and openly available resource characterizing the DNA methylation dynamics of glioblastoma progression in a highly annotated clinical cohort with matched MRI and detailed histopathological data. This work highlights the feasibility of establishing large, well-annotated patient cohorts out of routine clinical practice across multiple centers, using a national patient registry and a DNA methylation assay that is compatible with routinely collected FFPE samples. Given that robust protocols are available for measuring DNA methylation in routine clinical diagnostics 54 , epigenetic biomarkers are likely to contribute to improved diagnosis, prognosis, and personalized therapy in glioblastoma and other cancers.
URLs. Supplementary Website, http://glioblastoma-progression. computational-epigenetics.org/; TCGA, http://cancergenome.nih. gov/; WashU EpiGenome Browser (direct link to custom session for epigenome segmentations), http://epigenome-segmentation. computational-epigenetics.org.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0156-x.
with a RIN score below 5 were excluded (7 samples). Libraries for transcriptome profiling were prepared from a target amount of 1 µ g input RNA with the TruSeq Stranded mRNA LT sample preparation kit (Illumina) using Sciclone and Zephyr liquid handling workstations (PerkinElmer). Final library concentrations were quantified with the Qubit 2.0 fluorometric quantitation system, and the fragment size distribution was assessed using the Experion automated electrophoresis system. Individual libraries were diluted and pooled equimolarly, followed by sequencing on Illumina HiSeq 3000 and 4000 machines using the 50-bp single-read setup.
DNA methylation data processing. RRBS data were processed using a custom pipeline based on Pypiper (v0.2) (http://pypiper.readthedocs.io/) and Looper (v0.3) (http://looper.readthedocs.io/). Adapter sequences were trimmed, and 60-bp reads were cropped to 50 bp using Trimmomatic (v0.32) 55 . Trimmed reads were aligned to the human reference genome (GRCh38) using BSMAP (v2.90) in RRBS mode 56, 57 , and DNA methylation calling was performed with a Python script (biseqMethCalling.py) published previously 29 . To assess bisulfite conversion efficiency, unmapped reads were aligned to the spike-in reference sequences using Bismark (v0.12.2) 58 , and DNA methylation calls for methylated and unmethylated controls were extracted from the alignment file. CpGs in repetitive regions according to the UCSC RepeatMasker track were excluded from further analysis. DNA methylation was analyzed at single-CpGs resolution and in binned format with mean DNA methylation values calculated across 5-kb regions, CpG islands (as defined in the UCSC Genome Browser), enhancers in astrocytes (as defined by the Roadmap Epigenomics Project), or GENCODE promoter regions (1 kb upstream to 500 bases downstream of the annotated transcription start site).
DNA copy number analysis. Low-coverage whole-genome sequencing reads were aligned to human reference genome (GRCh38) using BWA's (v0.7.12) aln and samse commands 59 . Samtools (v1.4) was used for sorting and indexing the aligned short reads 60 . Copy number aberrations were detected with CNVkit (v0.9.1) 61 . This analysis relied on generating expected read counts in each genomic window (~50 kb) from a set of normal samples and calculating the log 2 ratios of the read counts from the tumor samples relative to the normal samples. We used 20 whole genome samples from the Genom Austria project (http://www.personalgenomes.org/ at/) to generate expected normal/germline read counts for each genomic window. In order to make the high-coverage Genom Austria data comparable with the lowcoverage tumor data, we downsampled them to 36 million reads with 50-bp read length. The batch pipeline recommended in the CNVkit manual (http://cnvkit. readthedocs.io/en/stable/pipeline.html#batch) was applied for generating reference values, calculating log 2 ratios in the tumor samples, segmentation of the log 2 ratios, and finally estimating the integer copy number values.
Copy number aberrations were also inferred from the RRBS data, using the R/ Bioconductor package 'CopywriteR' 62 applied to the BSMAP-aligned BAM files (bin size, 100 kb). Data from five normal brain controls were merged at the level of aligned BAM files to serve as the shared control for all analyses. Each individual sample was normalized either against the merged control or against the cohort median, whichever showed the less extreme (i.e., more conservative) value for a given bin. Genomic segments identified by CopywriteR were classified as amplified or deleted if their normalized absolute copy number value deviated more than one cohort s.d. (mean s.d. across all bins in a given segment) from zero. Amplified or deleted segments for each sample were plotted in an overview graph sorted by segment length.
RNA-seq data processing. RNA-seq data were processed as described previously 63 : adapter sequences were removed using Trimmomatic (v0.32) 55 , and only reads with a minimum length of 25 bp after adapter trimming were retained. Reads were aligned to the human transcriptome (GRCh38 including ncRNAs, Ensembl release 83) using Bowtie1 (v1.1) 64 , mapping up to 100 different positions for each read. Normalized transcriptwise expression estimates (RPKM values) were calculated on the basis of the transcriptome alignments using the R package 'BitSeq' (v1.14.0) 65 , running the getExpression() function with the 'uniform' option set to 'FALSE' .
Gene annotation and enrichment analysis. Glioblastoma associated genes from a recent publication 66 were annotated as oncogene, tumor suppressor gene, or drug resistance gene based on a published classification of cancer genes 67 . Genes not contained in this classification were manually annotated according to their known or suspected molecular functions as described in GeneCards (http://www. genecards.org). Enrichment analysis for gene sets and pathways was performed with Enrichr 68, 69 , using an R interface (https://github.com/definitelysean/enrichR) to query the Panther_2016 database (http://www.pantherdb.org/) for enrichments with an adjusted P < 0.05.
Patient survival analysis.
Kaplan-Meier survival analysis was performed using the functions survfit() and survdiff() of the R package 'survival' . For continuous variables, patients with values above the median were classified as 'high' and compared to those with values below the median (classified as 'low') unless indicated otherwise. Survival curves were plotted with ggsurvplot() from the R package 'survminer' . The significance of differences in OS or PFS was calculated using the log-rank test. Cox proportional hazards regression was performed using the function coxph() from the R package 'survival' .
Methods
Sample acquisition. All primary glioblastoma patients (IDH-wildtype status) were selected from the Austrian Brain Tumor Registry 27 (Supplementary Table 1 ). For the progression cohort, only patients with a first surgery at diagnosis and at least one additional surgery upon recurrence were included; for the validation cohort, only patients with one surgery at diagnosis and no further resective surgeries were included. Tumor samples and clinical data were provided by the following institutions: Medical University of Vienna (including Hospital Rudolfstiftung Vienna), Kepler University Hospital Linz, Paracelsus Private Medical University Salzburg, Medical University of Innsbruck, University Hospital of St. Poelten, State Hospital Klagenfurt, General Hospital Wiener Neustadt, and Medical University of Graz. All samples were deposited in the neurobiobank of the Medical University of Vienna (ethics vote EK078-2004). The progression cohort comprised 159 patients with matched FFPE samples for the primary tumor and at least one recurring tumor. After screening for sufficient tumor purity (> 50%), 47 patients were excluded and 112 patients were retained, each with at least two and up to four time points (283 tumor samples in total, including 6 patients with multisector sampling for spatial heterogeneity). The validation cohort comprised 105 patients with FFPE samples for the primary tumor. In all cases, the diagnosis of primary glioblastoma (IDH-wildtype status) was confirmed by central pathology review according to the 2016 update of the World Health Organization (WHO) classification 49 including targeted assessment of the IDH-R132H mutational status. In addition to the primary glioblastoma patients, 14 patients (33 tumor samples) with IDH-mutated oligodendroglioma/astrocytoma/glioblastoma and 5 patients (5 brain samples) who underwent temporal lobe surgery due to epilepsy (Medical University of Vienna) were included as controls. Informed consent was obtained according to the Declaration of Helsinki, and the study was approved and overseen by the ethics committee of the Medical University of Vienna (ethics votes EK550/2005, EK1412/2014, EK 27-147/2015).
DNA and RNA isolation. H&E-stained slides of all available FFPE blocks for a given patient and surgery were assessed for tumor cell content and tumor purity by an expert neuropathologist, and the most suitable FFPE block was selected for DNA extraction (for the 6 patients with multisector sampling, several distinct regions from one FFPE block were processed as separate samples). Where the tumor purity in the selected FFPE block was lower than 50%, vital tumor without artificial damage was enriched by macrodissection of the FFPE block (with secondary transferal of the region-of-interest to a new FFPE block) or by macrodissection of tissue shavings. Five tissue shavings per FFPE block cut at a thickness of 5 µ m each were used for DNA extraction with the QIAamp DNA FFPE Tissue Kit (Qiagen) following the manufacturer's instructions. In addition to the analysis of FFPE samples, matched DNA and RNA samples for validation of the subtype predictions were isolated from fresh-frozen tumor samples with the AllPrep DNA/RNA Mini Kit (Qiagen) following the manufacturer's instructions.
DNA methylation profiling by RRBS. RRBS was performed as described previously 29 using 100 ng of genomic DNA for most samples, while occasionally going lower (down to 2 ng) or higher (up to 200 ng) when DNA quantity and/ or quality was limiting (Supplementary Table 2 ). To assess bisulfite conversion efficiency independent of CpG context, methylated and unmethylated spike-in controls were added at a concentration of 0.1%. DNA was digested using the restriction enzymes MspI and TaqI in combination (as opposed to only MspI in the original protocol) to increase genome-wide coverage. Restriction enzyme digestion was followed by fragment-end repair, A-tailing, and adaptor ligation. The amount of effective library was determined by qPCR, and samples were multiplexed in pools of 10 with similar qPCR threshold cycle (C t ) values. The pools were then subjected to bisulfite conversion followed by library enrichment by PCR. Enrichment cycles were determined using qPCR and ranged from 12 to 21 (median, 16). After confirming adequate fragment size distributions on Bioanalyzer High Sensitivity DNA chips (Agilent), libraries were sequenced on Illumina HiSeq 3000 and 4000 machines using the 50-or 60-bp single-read setup.
Low-coverage whole-genome sequencing. Concentration and fragmentation of DNA extracted from fresh-frozen tumor tissue were assessed with the Qubit 2.0 fluorometric quantitation system (Life Technologies) and agarose gel electrophoresis, respectively. One sample with an insufficiently low DNA concentration was excluded. Libraries were prepared from 1 µ g input material using the TruSeq DNA PCR-Free HT Library Prep Kit (Illumina) with IDT for Illumina TruSeq UD Indexes (Integrated DNA Technologies). Briefly, genomic DNA was sheared using a Covaris S220 focused-ultrasonicator instrument, DNA fragments were cleaned and end-repaired, and a poly(A) tail was added to the 3′ end, followed by ligation of the sequencing adapters. After quality control, individual libraries were diluted, equimolarly pooled, and sequenced on Illumina HiSeq 3000 and 4000 machines using the 50-bp single-read setup.
RNA sequencing. The concentration of total RNA extracted from fresh-frozen tissue material was measured using the Qubit 2.0 fluorometric quantitation system (Life Technologies), and the quality was assessed by determining the RNA integrity number (RIN) with an Experion automated electrophoresis system (Bio-Rad). Samples query set, and the set of all differentially methylated tiling regions were used as background ('universe'). For a focused analysis, only region sets from astrocytes (as a differentiated cell type related to glioblastoma) and embryonic stem cells (as a highly undifferentiated cell type) in the LOLA Core database were included. P values were corrected for multiple testing using the Benjamini-Yekutieli (BY) method (p.adjust() in R), and all enrichments with an adjusted P < 0.001 were considered significant. In a control experiment, to assess potential effects of imbalance between hypermethylated and hypomethylated region sets, the analysis was repeated using the same number (defined by the minimum number of differentially methylated regions in either set) of highest-ranking regions from both sets. LOLA analysis was also applied to the regions identified as eloci in any patient. Here, all assessed loci were used as background (universe), all cell types in the LOLA Core database were included, and enrichments with a BY-corrected P < 0.001 were considered significant. Finally, for the analysis of regulatory regions predictive of survival, chromatin segmentations were obtained from the Roadmap Epigenomics Project 43 , transferred from genome assembly hg19 to hg38 using the liftOver tool 73 , and used in the region set enrichment analysis in replacement of the LOLA Core database. All regions considered by the machine-learning classifier were used as the LOLA background (universe), only region sets from astrocytes, brain tissue, and embryonic stem cells were included, and enrichments with a BY-corrected P < 0.001 were considered significant.
DNA methylation inferred regulatory activity (MIRA).
MIRA scores for selected sets of transcription factor binding sites from the LOLA Core database 42 or epigenome regulatory region sets from the Roadmap Epigenomics Project 43 (transferred from genome assembly hg19 to hg38 using the liftOver tool 73 ) were calculated as described previously 26, 74 . Briefly, aggregated DNA methylation profiles around the center of the designated sites (2.5 kb upstream and downstream, split into 21 bins) were created for each sample, and for each set of transcription factor-binding sites or genomic segmentation regions. MIRA scores were calculated as the log ratio between aggregated DNA methylation values for the center bin (bin 0, reflecting the center of the designated site) and the average of two flanking bins (bins -5 and + 5).
Immunohistochemistry. FFPE blocks were cut at a thickness of 3 μ m, and sections were stained on a Dako autostainer system using the following antibodies: CD3 NCL-l-END). Antigens were retrieved by heating the sections in 10 mM sodium citrate (pH 6.0) at 95 °C for 20 min, followed by antibody incubation for 30 min at room temperature. The Dako FLEX+ Mouse detection system was used according to manufacturer's recommendations. For antibodies against IDH1 (1:60 Dianova no. DIA-H09) and FoxP3 (1:25 BioLegend no. 320116), a Ventana BenchMark automated staining system was used, followed by visualization using the Ultra View detection kit. All sections were counterstained with hematoxylin. EZH2 (1:50 Cell Signaling Technology no. 5246) stainings were performed manually starting with antigen retrieval by heating the sections in 10 mM sodium citrate (pH 6.0) at 95 °C for 30 min, which was followed by antibody incubation for 12 h at 4 °C and visualization with the Dako EnVision detection system. For each antibody, positive and negative controls were included in every 30-slide batch. For negative controls, the primary antibody was omitted, and the Universal Negative Control rabbit (Dako) for polyclonal rabbit antibodies or purified mouse myeloma IgG1 (Zymed Laboratories, San Francisco, CA) for monoclonal mouse antibodies were used.
Histopathological analysis of whole-slide scans. Slides were scanned using a Hamamatsu NanoZoomer 2.0 HT slide scanner. The Hamamatsu NDP.view2 software was used to manually annotate relevant regions in the H&E slide scans (necrosis, hemorrhage, preexisting brain parenchyma, fibrotic scar, and artificially damaged tissue) by an expert neuropathologist. The remaining tissue area was assigned to the tumor. The H&E slide scans were downsampled to 10× magnification and exported using the NDPITools plugin in Fiji [75] [76] [77] along with XML files featuring the annotations. To obtain a cell nuclei mask, the Color Deconvolution method of Fiji was used to obtain an 8-bit greyscale image of the hematoxylin stain 78 . Automated local Phansalkar thresholding was used to segment cell nuclei (parameters, k = 0.2, r = 0.5, radius = 8) 79 , followed by the binary Close and Open operations. The Watershed method was used to separate clustered nuclei 80 . MATLAB R2014b (MathWorks) was used for further image analysis. The binary nucleus mask was analyzed in blocks of 160 × 160 pixels (~146 × 146 µ m). This block size was empirically found to provide a good compromise between the spatial resolution and nuclear content required for statistical analysis. The centroids of the nuclei were localized, and the nuclear density as well as morphological measures (nucleus area and eccentricity) were assessed in each block (using MATLAB's regionprops() function). In each block, the mean, s.d., coefficient of variation, median, and mode of the aforementioned characteristics were calculated. Using the binary annotation masks, each block was assigned to its Inference of transcriptional subtypes from RRBS data. Glioblastoma transcriptional subtypes were predicted from DNA methylation data at the level of single CpGs using L2-regularized logistic regression as implemented in the R package LiblineaR. Classifiers were trained and evaluated on Infinium 27k DNA methylation data for glioblastoma tumors 16 obtained from the TCGA data portal (https://portal.gdc.cancer.gov/). TCGA data were restricted to IDH-wildtype, non-G-CIMP tumors, resulting in a total of 172 samples that were included in the analysis. Furthermore, neural subtype samples were excluded because this subtype of glioblastoma had previously been associated with tumor margin and contamination with nontumor brain tissue 15, 41 . For each tumor sample in our cohort, a classifier was trained and evaluated on the TCGA data using those CpGs that were covered also in the sample of which the transcriptional subtype was to be predicted (1,417 CpGs on average). This approach was successful for all but two samples in which too few shared CpGs were covered for reliable prediction. After performance evaluation by tenfold cross-validation and calculation of the cross-validated receiver operating characteristic (ROC) area under curve (AUC) values, a final classifier was built using all selected TCGA samples. This classifier was used for RRBS-based prediction of the transcriptional subtype (including class probabilities) on the respective tumor sample.
Inference of transcriptional subtypes from RNA-seq data. To infer transcriptional subtypes from the RNA-seq data, we used the published set of subtype discriminatory genes, expression values, and subtype calls for the core TCGA samples from the study that first defined these transcriptional subtypes 40 . The corresponding data were obtained from the TCGA website (https://tcgadata.nci.nih.gov/docs/publications/gbm_exp/). We used these data to create reference expressions profiles for each of the three subtypes (classical, 38 samples; mesenchymal, 56 samples; proneural, 53 samples) by calculating subtype-wise average expression values for each of the 513 genes that had been assigned to one subtype. To simulate heterogeneity in terms of transcriptional subtype composition, we created all possible 'mix profiles' (n = 5,151) in steps of 1% from the three 'pure' reference profiles by calculating a weighted mean expression value for each of the genes. Finally, we calculated the Pearson correlation between the expression profile of the to-be-classified tumor samples and all 'mix profiles' . For visualization, all correlations for a given sample were color-coded and plotted in a triangular coordinate system using the R package 'ggtern' . The 'mix profile' with the highest correlation score for a given sample was used to determine the majority transcriptional subtype, and the highest correlation score itself was used as a measure of confidence in the RNA-based transcriptional subtype inference.
Differential DNA methylation analysis. Differentially methylated CpGs between groups of tumor samples (for example, transcriptional subtypes) were identified with a custom R script that uses a two-sided Wilcoxon rank-sum test. Groups containing less than five samples were excluded from the analysis, and only CpGs covered by at least five reads per sample in at least 30% of samples were included. CpGs in repetitive regions ('RepeatMasker' , 'Simple Repeats' , and 'WM + SDust' tracks from the UCSC Genome Browser, downloaded 6 September 2016) were also excluded. For the retained CpGs, differential DNA methylation between groups of samples was assessed using the wilcox.test() function in R, and P values were adjusted for multiple testing using the Benjamini-Hochberg method (p.adjust() in R). CpGs with multiple-testing adjusted P values less than 0.05 and with a median difference of beta values larger than 0.1 were considered significant.
Differentially methylated CpGs between sample pairs (i.e., primary tumor versus matched recurring tumor) were identified with a custom R script that uses a two-sided Fisher's exact test. This test was applied to the methylated and unmethylated read counts derived from the BSMAP-aligned reads by the biseqMethCalling.py script. P values were adjusted for multiple testing using the Benjamini-Hochberg method. To identify differentially methylated gene promoters, P values were combined using a generalization of Fischer's method 70 as implemented in RnBeads 71 . Promoter-specific DNA methylation levels for each sample were calculated as the mean of all CpGs in the promoter region. Promoter regions were defined as the genomic region 1 kb upstream to 500 bp downstream of a given transcription start site as annotated by GENCODE 72 . High-confidence differentially methylated promoters (Fig. 6 ) were defined by a DNA methylation difference greater than 75 percentage points, an adjusted P value below 0.001, and an average RRBS read coverage greater than 20 reads. A cohort-level trend ('max. trend' in Fig. 6b ) of DNA methylation changes during progression was defined on the basis of recurrently differentially methylated promoters (Fig. 6b) . 'Trend' patients were defined as those whose DNA methylation profiles were most similar to the max. trend (low normalized Manhattan distance); 'antitrend' patients were defined as those whose methylation profiles were most different from the max. trend (high normalized Manhattan distance) (Fig. 6c) .
Region-set enrichment analysis using LOLA. To identify shared biological patterns among the differentially methylated regions, the LOLA software was used to perform region-set enrichment analysis against a compendium of publicly available region sets 42 . To reduce potential biases from colocated CpGs, CpGs were merged into 1-kb tiling regions across the genome before LOLA analysis. The hypermethylated or hypomethylated regions were used as the LOLA was then calculated as the ratio of discordant reads compared to all valid reads covering that CpG. CpGs at the end of a read were disregarded to remove potential biases due to the end-repair step of RRBS library preparation. Because the PDR and epiallele entropy (EPY) calculation is highly sensitive to differences in the read composition of the underlying RRBS library, we focused this analysis on RRBS libraries with a similar number of PCR cycles (13) (14) (15) to ensure high consistency between samples (Supplementary Fig. 12a ).
The epiallele entropy (EPY), a measure of subclonality within a tumor, was calculated using a slightly modified version of methclone (v0.1) 50 . We calculated epiallele entropies separately for each of the samples and, independently, for each matched pair of primary and recurring tumors. Input files to methclone were created by aligning the trimmed RRBS reads to the human reference genome (GRCh38) using Bismark 58 . To find suitable thresholds for read coverage and entropy change, we performed a series of analyses with read thresholds set to 20, 40, and 60 reads and entropy change thresholds set to -40, -50, -60, -70, -80, and -90. We did not observe significant differences in the results except for the expected effects at the extremes of the spectrum. Therefore, we chose a moderate read threshold of 40 reads for methclone to consider a locus, and loci with a combinatorial entropy change below -80 were classified as epigenetic shift loci (eloci) between primary and recurring tumors or normal brain control samples (as described in the original publication) 50 . For each pair, we then calculated epiallele shifts per million loci (EPM), dividing the number of eloci by the total number of assessed loci normalized to 1 million loci 50 . Sample-wise PDR and epiallele entropy values were calculated by averaging across all promoters that were covered in > 75% of the samples. Promoter regions were defined as the genomic region 1 kb upstream to 500 bp downstream of a given transcription start site as annotated by GENCODE 72 .
Statistics and reproducibility. All boxplots were created using the geom_boxplot() function of the R package 'ggplot2' with standard settings. The upper and lower hinges represent the 75th and 25th percentiles, respectively. The center line represents the median. The whiskers extend to the largest and smallest values within 1.5 times the interquartile range. All violin plots were created using the geom_violin() function of the R package 'ggplot2' with standard settings, representing data point density along the y axis. P values in the enrichment analyses (LOLA, region sets; Enrichr, gene sets) were calculated using a twosided Fisher's exact test. Adjustment for multiple testing was performed using the Benjamini-Yekutieli (BY) method (LOLA) and the Benjamini-Hochberg (BH) method (Enrichr). P values accompanying Kaplan-Meier analysis were calculated using a two-sided log-rank test. No adjustment for multiple testing was performed. P values indicating the statistical significance of differences between groups of samples in continuous histopathological, MRI, and molecular variables were calculated using a two-sided Wilcoxon rank sum test. No adjustment for multiple testing was performed. P values indicating the statistical significance of correlations were calculated using a two-sided Pearson's test. Shaded regions around central estimates in ROC curves, Kaplan-Meier plots, and scatterplots denote 95% confidence intervals. Histopathology and MRI pictures represent individual patients and are provided for illustration. Multidimensional scaling analysis was performed by calculating the Euclidean distance between samples using the R dist() function, followed by multidimensional scaling using the R isoMDS() function.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. All data are available through the Supplementary Website (http://glioblastoma-progression.computational-epigenetics.org/). Genome browser tracks support locus-specific inspection of the DNA methylation data, and a graphical data explorer enables interactive analysis of associations in the dataset (Supplementary Fig. 13 ). The Supplementary Website also provides lists of regions predictive of immune cell infiltration; precomputed R objects with DNA methylation profiles and clinical annotation data for follow-up analysis; raw and segmented histopathological image data; and raw as well as segmented MRI data. The processed DNA methylation data are also openly available from the NCBI Gene Expression Omnibus (GEO) repository (accession number: GSE100351), and the raw sequencing data are available from EBI European genome-phenome archive (EGA) (accession number: EGAS00001002538) as controlled access. To protect patient privacy, interested researchers need to apply via a data access committee, which will grant all reasonable requests by bona fide researchers. Finally, in the spirit of reproducible research 86 , the Supplementary Website makes the source code underlying the presented analyses publicly available.
corresponding region if > 90% of the pixels in that block were uniformly annotated. Subsequently, for each annotated region, the mean, s.d., coefficient of variation, median, and mode of the previously obtained block-specific statistical parameters were calculated.
For automated analysis of scanned immunohistochemical slides, whole-slide scans were downsampled to 5× magnification. First, the color deconvolution method of Fiji was used to separate the hematoxylin from the DAB stain. The 8-bit greyscale hematoxylin-and DAB-stained images were then each thresholded using Phansalkar thresholding, and stained cells and nuclei were counted with the Analyze Particles algorithm. For each slide, DAB + cells were normalized to the total cell count.
Radiological evaluation of patients with glioblastoma. MR images of sufficient quality for first diagnosis as well as recurrence were available for 54 of the patients with glioblastoma included in this study, which were contributed by six radiology departments. The dataset included T1-weighted images with contrast enhancement (CE) and fluid-attenuated inversion recovery (FLAIR) and T2-weighted axial images, which were reviewed for topographic tumor location to assess solitary vs. multicentric tumors and local vs. distant recurrences. Multicentric glioblastomas were defined as at least two spatially distinct lesions that are not contiguous and whose surrounding abnormal FLAIR/T2 signals do not overlap 81 . Tumor segmentation was performed with BraTumIA 82 , which uses multimodal MRI sequences for fully automated volumetric tumor segmentation. T1, T1 contrast enhanced, T2, and FLAIR sequences were used to segment four tumor tissue types: necrotic, cystic, edema/nonenhancing, and enhancing tumor. Because of differences in MRI protocols across the study sites, the multimodal sequences were affine registered to the T1 sequence with SPM122 and resampled to 1 × 1 × 3 mm voxel size before segmentation. The BraTumIA-derived segmentations were reviewed by an expert radiologist, and errors in the automatic segmentation were manually corrected.
Evaluation of MRI-based progression phenotypes. MRI-based tumor progression was assessed according to the Response Assessment in NeuroOncology (RANO) standard 83 . Serial T1-weighted images with CE and FLAIR/ T2-weighted images were available for 43 patients. Progression subtypes were classified as described previously 47, 84 : (i) classic T1 (incomplete disappearance of T1-CE during therapy followed by T1-CE increase at progression), (ii) cT1 relapse/flare-up (complete disappearance of T1-CE during therapy followed by T1-CE reoccurrence at progression), (iii) primary nonresponder (increase and/or additional T1-CE lesions at first MRI follow-up after start of therapy), (iv) T2-circumscribed (bulky and inhomogeneous T2/FLAIR progression, no or single faintly speckled T1-CE lesions at progression), and (v) T2-diffuse (complete decrease in T1-CE during therapy but exclusive homogeneous T2/FLAIR signal increase with mass effect at progression).
DNA methylation-based prediction of tumor properties. Tumor properties such as immune cell infiltration and tumor cell morphology were predicted from DNA methylation data using a machine-learning approach based on the R package LiblineaR. The DNA methylation data were prepared by calculating for each sample the mean DNA methylation levels in 5-kb tiling regions across the genome. Tiling regions covered in < 90% of the samples and samples covering < 80% of the selected tiling regions were excluded from the analysis, and the filtered data matrix (samples × tiling regions) was subjected to imputation using the function impute. knn() from the R package 'impute' , with the parameter k (i.e., the number of nearest neighbors considered) set to 5. Tumor properties represented by continuous response variables were converted into categorical variables by setting the 20% highest values to 'high' , the 20% lowest values to 'low' , and the remaining samples to 'NA' (missing value). Imputed beta values were used to train and evaluate the classifiers using LiblineaR(). In the confirmatory hierarchical clustering based on the most predictive features identified by the classifiers, the beta values were scaled across samples prior to clustering, but displayed in the heatmap as unscaled beta values for better visualization and comparability. LiblineaR() was set to use support vector classification by Crammer and Singer 85 as model type, and the appropriate cost parameter was estimated from the imputed data matrix using the function heuristicC() from the same package. For each tumor property, the performance of the classifiers was determined through tenfold crossvalidation, and 100 control runs with randomly shuffled labels were included to detect potential overfitting. ROC curves and ROC AUC values were determined using the functions prediction() and performance() of the R package 'ROCR' . Finally, we trained a classifier on the entire dataset using the selected model and cost parameter, which was then used for further analysis including the extraction of the most predictive features, hierarchical clustering, and the prediction of additional samples (for the transcriptional subtypes and for model testing in the validation cohort).
Estimation of DNA methylation heterogeneity. The proportion of discordant reads (PDR), a measure of DNA methylation erosion and disorder, was calculated as described in the original publication 25 . Briefly, the number of concordantly or discordantly methylated reads with at least four valid CpG measurements was determined for each CpG using a custom Python script. The PDR at each CpG 1 nature research | life sciences reporting summary Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined. Sample size was not predetermined but the result of selecting all patients/samples that fulfilled the inclusion criteria described in the Methods section. The progression cohort was restricted to patients that had undergone tumor resection at least twice, while no such condition was used for the validation cohort.
Data exclusions
Describe any data exclusions. We found a high level of discrepancies between assigned and inferred patient sex specifically in one out of three microwell plates of biobank-derived genomic DNA designated for the validation cohort. To avoid corrupting our dataset with possibly contaminated samples, we excluded all samples from the affected microwell plate.
Replication
Describe whether the experimental findings were reliably reproduced.
The bioinformatic analysis makes extensive use of cross-validation in order to assess robustness and reproducibility. No further replication was attempted.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In the machine learning analysis, individual patients/samples were randomly assigned to the training or test set using the R function createFolds().
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Not applicable (patients were treated according to established standards of clinical care with no blinding nor randomization)
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section) 
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
As described in the Methods section, this study investigates a progression cohort of adult patients with primary glioblastoma who underwent tumor resection at diagnosis and at least once upon tumor recurrence. These patients were selected through the Austrian Brain Tumor Registry. Only patients with at least two subsequent surgeries were included in the progression cohort, which is associated with favorable tumor location within the brain and adequate patient performance. These patients are on average younger (median age at diagnosis: 58 years) and survive longer (median overall survival: 23.9 months) compared to the unselected patient population. To account for this bias, a validation cohort was included that is broadly representative of the Austrian patient population for primary glioblastoma.
